Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Middleton

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaB W Hancock, K Wheatley, S Harris, et al.
British Journal of Cancer|September 29, 2005
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western populationR O Illing, J E Kennedy, F Wu, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
The British Journal of Radiology|June 19, 2008
High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?T A Leslie, J E Kennedy, R O Illing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trialV Urbonas, D Schadendorf, L Zimmer, et al.
British Journal of Cancer|April 16, 2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanomaR F Kefford, N P B Thomas, P G Corrie, et al.
Journal of Medicinal Chemistry|December 19, 1998
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chainR S McElhinney, D J Donnelly, J E McCormick, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaB W Hancock, K Wheatley, S Harris, et al.
British Journal of Cancer|September 29, 2005
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western populationR O Illing, J E Kennedy, F Wu, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
The British Journal of Radiology|June 19, 2008
High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?T A Leslie, J E Kennedy, R O Illing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trialV Urbonas, D Schadendorf, L Zimmer, et al.
British Journal of Cancer|April 16, 2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanomaR F Kefford, N P B Thomas, P G Corrie, et al.
Journal of Medicinal Chemistry|December 19, 1998
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chainR S McElhinney, D J Donnelly, J E McCormick, et al.
Pageof 6